Almost universally, diagnosed cancer patients find themselves asking, "Why me?" Even though medical research has yet to find a precise scientific answer, we do know enough about lymphocyte biology to make some educated inferences about the cause of lymphoma and chronic lymphocytic leukemia (CLL). Read more.
As a patient recently diagnosed with lymphoma, sifting through all the new information can be overwhelming. With up to 100 different forms, lymphomas are not the most easily categorized of cancers. Read more.
Bud Thoms first noticed the lump in his neck in early 2003. He didn't tell his wife, Delores, because they were planning a month-long trip to visit relatives on the East Coast. He felt fine. But by September, when they returned, Bud, 69 at the time, couldn't hide it from Delores any longer. A visit to his primary care physician occurred that September, followed by a biopsy that confirmed the PCP's suspicions: Bud had mantle cell lymphoma, an aggressive cancer that develops in the lymph system, responsible for defending the body against infection. Read more.
In a series of video interviews with Dr. Jeff Sharman, Willamette Valley Cancer Institute and Research Center (WVCI) oncologist and hematologist, Dr. Brian Koffman discusses with Dr. Sharman a range of topics of interest to CLL patients. Read more.
Clinical trials overseen by hematologist oncologist Dr. Jeff Sharman at Willamette Valley Cancer Institute and Research Center (WVCI) contributed to FDA approval of a breakthrough drug for chronic lymphocytic leukemia (CLL), a blood and bone marrow disease. Read more.
Dr. Jeff Sharman, a hematologist oncologist at Willamette Valley Cancer Institute and Research Center, was recently interviewed in Cologne, Germany, about new drugs for chronic lymphocytic leukemia (CLL), and access to them through clinical trials. Read more.
Dr. Jeff Sharman, a hematologist oncologist at Willamette Valley Cancer Institute and Research Center, was published in the New England Journal of Medicine last week for clinical trials held at WVCI on a breakthrough drug for chronic lymphocytic leukemia (CLL). Read more.
Dr. Sharman shares a Focus Forward Films feature with Ross Kauffman discussing a new development for patients with B cell cancer. Read more.
Dr. Jeff Sharman, research director at WVCI, compares the remarkable advances in HIV medicines to the great strides in the treatment of blood cancers due to clinical trials. Read more.
The first two chronic lymphocytic leukemia (CLL) patients ever in the world to receive a new, potentially life-saving drug for B-cell cancers were part of a clinical trial run by Dr. Jeff Sharman at WVCI. Read more.
Dr. Sharman is highlighted in this U.S. Oncology Network video focusing on his blood cancer research and his studies in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). Read more.
It's an exciting time in cancer research, especially concerning chronic lymphocytic lymphoma (CLL). Dr. Jeff Sharman, Willamette Valley Cancer Institute and Research Center's research director, specializes in CLL and presented studies at the American Society of Hematology conference in December. Read more.
While in Atlanta for the conference, he sat down for an interview with Dr. Andrew Schorr of Patient Power to talk about CLL research and how the direction of treatment is changing, from traditional chemotherapy to targeted therapies...
As if she's preparing for a storm, Alicia Heer "watches and waits
" to see if her husband's cancer will stay at bay or progress.
"It's hard to accept not doing anything," Alicia says. "Sometimes, I call it 'wait and worry.' We know something bad is inside of him, and we want it out. But there's no way to eradicate it, and we don't have control."
Comfortably settled into an infusion chair in his preferred corner of the chemo suite, Jay Sperling smiles as he recounts the winding road he traveled to get here.
Back in 2002, when he was diagnosed with chronic lymphocytic leukemia (CLL), many of today's treatments were unavailable. That's the beauty of clinical trials, he notes, there's always something new being developed and tested... Read more.
"I have leukemia, but I'm lucky," says Betty Hemmingsen.
Diagnosed with chronic lymphocytic leukemia (CLL) in April 2011, Betty participated in a clinical trial at Willamette Valley Cancer Institute and Research Center. Sixteen months later, she learned her cancer was inactive... Read more.
On Friday, Sept. 14, Siuslaw Bank will host its second annual Good Will Grill to raise money for the Leukemia & Lymphoma Society. Last year, the inaugural event raised $30,000 to fight blood cancers. Read more.
The event is organized by Siuslaw Bank employee Jeff Gusinow, who was diagnosed with follicular lymphoma in 2006. Since 2009, Willamette Valley Cancer Institute's Dr. Jeff Sharman has been his oncologist. Learn more about Gusinow's story here...
Wow! What a wonderful turnout we had at Relay For Life of Eugene/Springfield. Words canâ€™t begin to express the overwhelming joy we felt taking part in this fun, emotional and memorable event.
Friday night began with an opening ceremony, including remarks from our very own medical oncologist Dr. Jeff Sharman. He connected with everyone there, speaking directly from the heart with his inspiring words. Then, hundreds of survivors took to the track for the first lap, as the rest of us stood by cheering them on...
On Sunday, June 10, two front-page articles of The Register-Guard featured Willamette Valley Cancer Institute and Research Center.
"Fighting Cancer: Springfield doctor leads trials for breakthrough treatments" highlights clinical trials directed by Dr. Jeff Sharman... Read more.
By targeting specific gene mutations, doctors can now use personalized medicine to treat cancer based upon unique features that caused it to grow.
Medical oncologist Dr. Jeff Sharman is helping lead the way in personalized medicine through research and clinical trials at Willamette Valley Cancer Institute and Research Center. Recently, he spoke at the Oregon Bioscience Association Conference about advances in cancer treatment.
â€œThere are multiple ways a cancer can begin within a single part of the body,â€ Sharman says...
An accurate cancer diagnosis is an integral part of planning for treatment. Patients who come to Willamette Valley Cancer Institute can now benefit from imaging technology new to Lane County and available at Oregon Imaging Centers, which was recently accredited for both oncological and neurological imaging procedures.
PET/CT exams are the most effective method for diagnosing or ruling out certain types of cancer, as well as coronary heart disease and brain disorders, such as Alzheimerâ€™s and Parkinsonâ€™s diseases...